(Q37136801)

18 August 2017

1 reference

title

Testosterone surge: rationale for gonadotropin-releasing hormone blockers? (English)

1 reference

18 August 2017

1 reference

1 reference

Hendrik van Poppel

1

1 reference

PubMed ID

18407326

18 August 2017

Sten Nilsson

series ordinal

2

1 reference

PubMed ID

18407326

18 August 2017

language of work or name

English

0 references

publication date

14 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

71

1 reference

18 August 2017

6

1 reference

18 August 2017

1001-1006

1 reference

Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Gonadotropin-releasing-hormone-receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Is the flare phenomenon clinically significant?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

The 'flare' phenomenon: should we be concerned?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

EAU guidelines on prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Estimated impact of the Prostate Cancer Prevention Trial on population mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.070

10.1016/J.UROLOGY.2007.12.070

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18407326